Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹78 Cr
Revenue (TTM)
₹57 Cr
Net Profit (TTM)
₹7 Cr
ROE
65.4 %
ROCE
46.3 %
P/E Ratio
11.5
P/B Ratio
1.7
Industry P/E
35.17
EV/EBITDA
7.7
Div. Yield
0 %
Debt to Equity
0.9
Book Value
₹18.7
EPS
₹8.3
Face value
10
Shares outstanding
11,116,000
CFO
₹--
EBITDA
₹--
Net Profit
₹--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Accretion Pharmaceuticals
| -16.3 | 9.0 | -15.2 | -- | -- | -- | -- |
|
BSE Healthcare
| -4.4 | -4.9 | -5.6 | 2.5 | 23.5 | 14.0 | 10.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Accretion Pharmaceuticals
|
73.5 | 77.8 | 57.4 | 6.8 | -- | 65.4 | 11.5 | 1.7 |
| 2,212.4 | 18,134.5 | 1,215.1 | 284.8 | 28.7 | 21.1 | 63.2 | 11.9 | |
| 656.0 | 12,802.2 | 7,266.8 | 627.5 | 11.9 | 12.6 | 20.4 | 2.3 | |
| 644.0 | 15,690.5 | 5,092.5 | 545.5 | 15.9 | 14.1 | 28.8 | 3.8 | |
| 854.3 | 13,526.2 | 7,918.4 | 429.9 | 10.7 | 7.2 | 31.3 | 2.0 | |
| 1,028.6 | 18,439.4 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 11.8 | 2.1 | |
| 1,408.1 | 16,167.3 | 1,419.3 | 20.1 | 8.4 | 0.5 | 804.3 | 2.8 | |
| 141.5 | 18,702.5 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.4 | |
| 399.4 | 16,028.9 | 3,720.2 | 352.1 | 13.7 | 8.2 | 45.5 | 3.4 | |
| 1,273.9 | 20,664.1 | 3,151.0 | -10.0 | 8.4 | 2.5 | 939.3 | 4.5 |
No Review & Analysis are available.
--
Incorporated
2023
Chairman
Harshad Nanubhai Rathod
Managing Director
Vivek Ashok Kumar Patel
Headquarters
Ahmedabad, Gujarat
Website
Looking for more details about Accretion Pharmaceuticals Ltd’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The share price of Accretion Pharmaceuticals Ltd is ₹73.50 (NSE) as of 06-Apr-2026 15:31 IST. Accretion Pharmaceuticals Ltd has given a return of --% in the last 1 years.
The P/E ratio of Accretion Pharmaceuticals Ltd is 11.45 times as on 02-Apr-2026, a 67 discount to its peers’ median range of 35.17 times.
The P/B ratio of Accretion Pharmaceuticals Ltd is 1.73 times as on 02-Apr-2026, a 46 discount to its peers’ median range of 3.21 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
0.00
|
0.00
|
|
2024
|
0.00
|
0.00
|
|
2025
|
0.00
|
0.00
|
|
2024
|
0.00
|
0.00
|
The 52-week high and low of Accretion Pharmaceuticals Ltd are Rs 102.50 and Rs 53.80 as of 06-Apr-2026.
Accretion Pharmaceuticals Ltd has a market capitalisation of ₹ 78 Cr as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Accretion Pharmaceuticals Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹3.50
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.